Legend Biotech shares jump 40% after promising early CAR-T data in Non-Hodgkin’s lymphoma
Shares of Legend Biotech rose more than 40% after the company released early results from its in vivo CAR‑T therapy targeting Non‑Hodgkin’s lymphoma. The data showed encouraging activity and a manageable safety profile, prompting optimism among investors.
The therapy, designed to deliver engineered T cells directly inside the body, aims to improve efficacy over traditional CAR‑T approaches. Early patient responses suggest the treatment could address a significant unmet need in aggressive lymphoma subtypes.
The stock rally stood out amid a broader market sell‑off for biotech stocks, highlighting Legend Biotech as a rare winner in a challenging trading day. The article also referenced new guidance for gene‑therapy developers and a separate licensing deal by Eli Lilly, underscoring a busy week for the sector.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Legend Biotech emerged as a rare market winner”
read at STAT ↗
comments(0)
5-min edit window · permanent after that